Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that President and CEO Christopher U. Missling, PhD, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at the Westin St. Francis Hotel in San Francisco, CA. Anavex is focused on developing therapeutics for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Their lead drug, ANAVEX®2-73 (blarcamesine), has shown promise in Phase 2 trials for Alzheimer’s and Parkinson’s disease dementia, indicating its potential to treat various CNS disorders. A live webcast of the presentation will be available online.
- None.
- None.
Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time at the Westin St. Francis Hotel in San Francisco, CA.
A live webcast of the presentation, as well as an archived recording, will be available at https://jpmorgan.metameetings.net/events/healthcare22/sessions/40488-anavex-life-sciences-corp/webcast?gpu_only=true&kiosk=true and in the Investors section of the Company's website at www.anavex.com.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), successfully completed a Phase 2a clinical trial for Alzheimer’s disease and recently a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
When will Anavex Life Sciences present at the J.P. Morgan Healthcare Conference?
What is Anavex Life Sciences' lead drug candidate?
What therapeutic areas does Anavex Life Sciences focus on?
Where can I watch the Anavex Life Sciences presentation?
What is the stock symbol for Anavex Life Sciences?
What recent studies have been conducted by Anavex Life Sciences?
